Is Arrowhead Pharmaceuticals Close to a Cure for HBV?

Arrowhead Pharmaceuticals (NASDAQ: ARWR) saw its stock price rise from $20 to over $70 last year on the basis of no news. A similar decline occurred in reverse this year -- again on the basis of no material news whatsoever. Massive speculation on the stock may be related to its flagship candidate, ARO-HBV, which has demonstrated in clinical trials to best efficacy against current standards of care for combating the hepatitis B virus (HBV). Is this potentially a functional cure for the condition, or have investors become too hyped on its potential? Let's find out together.